Eyenovia (EYEN) IPO Opens Flat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq rise as soft inflation data, bank earnings buoy sentiment
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Eyenovia Announces Pricing of Initial Public Offering
January 25, 2018 6:30 AM ESTNEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (Eyenovia), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the pricing of its initial public offering of 2,730,000 shares of common stock at a price of $10.00 per share. In addition, Eyenovia has granted the underwriters a 30-day option to purchase up to an additional 409,500 shares of common stock at the initial public offering price, less the underwriting discounts and commission, to cover overallotments if any. The gross proceeds to Eyenovia from the initial public... More
